Bank of America analyst Wamsi Mohan raised IBM's 12-month price target to $330 from $315, reflecting an expected 11.13% gain from the current price of $296.94. The upgrade is driven by anticipated modest increases in IBM's FY26 revenue and free cash flow guidance, faster-than-expected benefits from the Confluent acquisition, and strong growth in IBM's software and infrastructure segments. Confluent is projected to contribute $340 million in Q2 revenue, boosting software growth by about 5%. The shift toward higher-margin software is enhancing IBM's free cash flow and supporting long-term prospects in quantum computing. If IBM's stock breaks through its current resistance level, the bullish target could be reached.
The global generative AI in healthcare market, valued at $1.84 billion in 2024, is projected to grow at a 31.4% CAGR to reach $21.64 billion by 2034. Growth is fueled by solutions for medical imaging, diagnostics, drug discovery, and administrative a...
Scientists from Oak Ridge National Laboratory, Cleveland Clinic, and IBM have used quantum-centric supercomputing to calculate molecular configurations of FLiBe, a key material for extracting tritium fuel in fusion reactors. Tritium is rare but essen...
